Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner’s New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema ...

Gemini 2.5 Pro represents a significant step forward in AI model design, combining raw power with refined reasoning ...

Regent Craft secures a contract from the U.S. Marine Corps to advance high-speed, radar-evading electric seagliders for ...

Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...

Received a "Study May Proceed” letter from the FDA to evaluate amezalpat in combination with atezolizumab (TECENTRIQ®) and ...

Q4 2024 Management View CEO George Lasezkay highlighted the company's progress in advancing its suprachoroidal delivery platform, noting over 15,000 suprachoroidal injections performed to date. He ...

As fears of a recession loom large, some people have begun to reevaluate their spending habits. A small but potentially ...

PRESS RELEASE Urteste plans to start clinical trials for its pancreatic cancer test in Europe in Q3 2025 Gdansk, Poland - 27 March 2025 - Urteste S.A. (Warsaw Stock ...

The AI tool helps with SoC design checks by handling logic verification, automating ECOs, and checking low-power designs.

Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class ...

At this time, I would like to welcome everyone to the Pulse Biosciences’ Fourth Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the ...

"We are excited to welcome Gerard to the Beta Bionics Board,” said Sean Saint, President and Chief Executive Officer of Beta ...